<DOC>
	<DOCNO>NCT00997750</DOCNO>
	<brief_summary>The purpose study determine whether nonsteroidal antiinflammatory drug lornoxicam combination low dose aspirin ( 100mg/day ) effective safe patient Acute Coronary Syndrome without persistent ST-segment elevation .</brief_summary>
	<brief_title>Efficacy Safety Lornoxicam Patients With Acute Coronary Syndrome</brief_title>
	<detailed_description>Nonsteroidal Antiinflammatory drug ( NSAIDs ) frequently prescribe drug world . There lot controversial information publish recent year NSAID cardiosafety . It still unclear NSAIDs develop cardioprotective cardiotoxic effect acute chronic heart disease patient . Aim study investigate safety efficacy Lornoxicam , nonselective COX-inhibitor , patient acute coronary syndrome without ST-segment elevation ( NSTEACS ) evaluate influence Lornoxicam C-reactive protein ( CRP ) IL-6 , IL-10 level .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Lornoxicam</mesh_term>
	<mesh_term>Piroxicam</mesh_term>
	<criteria>1 . Unstable angina verify first 48 hour admit hospital 2 . Acute Miocardial infarction without Stsegment elevation verify first 48 hour admit hospital 1 . High risk bleed location 2 . Any kind acute active inflammatory process ( exclude acute coronary syndrome ) 3 . Aspirin NSAID Intolerability 4 . No informed consent 5 . Acute peptic stomach duodenum ulcer 6 . Acute chronic renal failure ( serum creatinin &gt; 300 mmol/l ) 7 . Acute cerebrovascular bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>ACS</keyword>
	<keyword>Acute Coronary Syndrome</keyword>
	<keyword>NSAID</keyword>
	<keyword>Lornoxicam</keyword>
	<keyword>Xefocam</keyword>
</DOC>